CTOs on the Move

Enliven Therapeutics

www.enliventherapeutics.com

 
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Western Slope Labs

Western Slope Labs is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BHPI

At Behavioral Health Professionals, Inc. we take pride in offering expert behavioral health management services. It’s all we do.

Medvantx

Medvantx Pharmacy Services helps pharmaceutical brands do more than just survive in an ever-changing marketplace - we help them thrive in it. Medvantx provides powerful and personalized support to healthcare partners (HCPs) and their patients. We service the specialty needs of pharmaceutical manufacturers by offering patient assistance programs and providing efficient intake solutions, nationwide dispense and fulfillment services, quality aftercare through counseling and customer service, safe and secure data handling, dependable inventory management and logistics, and insightful reporting and accounting. Serving more than 50 pharmaceutical manufacturers and managing more than $7.5 billion B of prescriptions annually, Medvantx has been redefining pharmacy for over 20 years.

Amt Labs Inc

Amt Labs Inc is a North Salt Lake, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.